Subscribe to RSS
DOI: 10.1055/s-2003-40844
Bis(1,3,4-Thiadiazolo)-1,3,5-triazinium Halides: Access to Highly Substituted Aromatic Guanidines [1]
Publication History
Publication Date:
24 July 2003 (online)
Abstract
The reaction of bis(1,3,4-thiadiazolo)-1,3,5-triazinium halides with primary aromatic amines in CHCl3/Et3N yields new highly substituted aromatic guanidines (up to 90% yield).
Key words
guanidinylation - nitrogen heterocycles - nucleophilic addition - rearrangements - sulfur heterocycles
-
1a
Part 7 in the series ‘Bis(1,3,4-Thiadiazolo)-1,3,5-triazinium Halides’. Part 6, see: Nilson Lill, St. O.; Rauhut, G.; Anders, E. Chem.-Eur. J. 2003, in press.
-
1b Part 5, see:
Wermann K.Walther M.Günther W.Görls H.Anders E. Eur. J. Org. Chem. 2003, 1389 -
1c Part 4, see:
Wermann K.Walther M.Anders E. ARKIVOC 2002, 10: 24 -
2a
Berlinck RGS. Nat. Prod. Rep. 2002, 19: 617 -
2b
Berlinck RGS. Nat. Prod. Rep. 1999, 16: 339 -
2c
Hannon CL.Anslyn EV. Bioorg. Chem. Front. 1993, 3: 193 - 3
Ishikawa T.Isobe T. Chem.-Eur. J. 2002, 8: 553 - 4
Costa M.Chiusoli GP.Taffurelli D.Dalmonego G. J. Chem. Soc., Perkin Trans. 1 1998, 1541 - 5
Heinisch G.Matuszak B.Rakowitz D.Mereiter K. J. Heterocycl. Chem. 2002, 39: 695 -
6a
Isobe T.Fukuda K.Ishikawa T. J. Org. Chem. 2000, 65: 7770 -
6b
Isobe T.Fukuda K.Tokunaga T.Seki H.Yamaguchi K.Ishikawa T. J. Org. Chem. 2000, 65: 7774 -
6c
Isobe T.Fukuda K.Yamaguchi K.Seki H.Tokunaga T.Ishikawa T. J. Org. Chem. 2000, 65: 7779 -
7a
Feichtinger K.Zapf C.Sings HL.Goodman M. J. Org. Chem. 1998, 63: 3804 -
7b
Feichtinger K.Sings HL.Baker TJ.Matthews K.Goodman M. J. Org. Chem. 1998, 63: 8432 -
8a
Katritzky AR.Rogovoy BV.Chassaing C.Vvedensky V. J. Org. Chem. 2000, 65: 8080 -
8b
Kim H.-O.Mathew F.Ogbu C. Synlett 1999, 193 -
8c
Guo Z.-X.Cammidge AN.Horwell DC. Synth. Commun. 2000, 30: 2933 -
10a
Anders E.Wermann K.Wiedel B.Günther W.Görls H. Eur. J. Org. Chem. 1998, 2923 -
10b
Anders E.Vanden Eynde J.-J.Wermann K. In Advances in Heterocyclic Chemistry Vol. 77:Katritzky AR. Academic Press; New York: 2000. p.183 -
11a
Wermann K.Walther M.Günther W.Görls H.Anders E. J. Org. Chem. 2001, 66: 720 -
11b
Walther M.Wermann K.Görls H.Anders E. Synthesis 2001, 1327 - 12
Van der Plas HC. In Advances in Heterocyclic Chemistry Vol. 74:Katritzky AR. Academic Press; New York: 1999. p.87 - 13 Besides 7b, N-(4-methylphenyl)-N-[(1E)-(4-methyl-phenyl) methylene]amine
was isolated in almost quantitative yield by the reaction of 2b and 4-methyl benzaldehyde formed in situ,
see:
Bolognese A.Diumo MV.Mazzoni O.Giordano F. Tetrahedron 1991, 47: 7417 - 14
Tripathy PB.Rout MR. J. Indian Chem. Soc. 1960, 37: 414 - 15
Dubenko RG.Benzina IN.Pel’kis PS. Zh. Obshch. Khim. 1963, 33: 274 - 17
Chubb FC.Nissenbaum J. Can. J. Chem. 1959, 37: 1121
References
See ref. [5] [7a] [8] and literature cited therein.
16The iminium salt 8a (R1 = 4-MePh; R2 = Me): Identification by HMQC experiments showing a CH correlation between δ = 160.7 and 8.45 ppm. 1H NMR (400 MHz, CDCl3): δ = 2.34 (s, 3 H, CH3), 2.46 (s, 3 H, CH3), 7.79 (d, 2 H, aryl-CH), 7.25 (d, 2 H, aryl-CH), 7.31 (br s, 1 H, NH), 8.45 (s, 1 H, imine-CH). 13C NMR (100.6 MHz, CDCl3): δ = 17.5, 21.7, 129.2, 129.3, 132.8, 142.6, 150.9, 160.7 (imine-CH, broad), 170.0.
18The hydrolysis products 9 and 10 were unambiguously identified by TLC (EtOAc), GC, derivatization with 2,4-dinitrophenylhydrazine, and 1H and 13C NMR spectroscopy in DMSO-d 6.
19
General Procedure
for the Preparation of Guanidines 6: To a well-stirred mixture
of the corresponding bis-(1,3,4-thiadiazolo)-1,3,5-triazinium halide 1 (5 mmol) and amine 2 (5
mmol) in 30 mL CHCl3, Et3N (30 mL) was added gradually
at r.t. After stirring over a period of 24 h, the resulting suspension
was concentrated in vacuo. The residue was washed with cold water
and extracted three times with CHCl3. The combined extracts
were dried with Na2SO4 and concentrated in
vacuo. The residues were purified by column chromatography (silicagel
60; eluting with EtOAc; pentane/EtOAc; Et2O/EtOAc)
or by fractional crystallization from EtOH, MeCN, EtOAc.
All
new compounds 6 were fully characterized.
Selected analytical data:
5-Methyl-2-(4-methylphenyl)-
N
′-(5-methyl-1,3,4-thiadiazol-2-yl)-
N
-phenyl-1,3,4-thiadiazole-3(2
H
)-carboximidamide (6a): Recrystallized from EtOH. 1H NMR
(250 MHz, CDCl3): δ = 2.00
(s, 3 H, CH3), 2.26 (s, 3 H, CH3), 2.44 (s,
3 H, CH3), 7.19 (s, 1 H, 2-CH), 6.96-7.22 (m,
9 H, CHph), 10.04 (s, 1 H, NH). 13C
NMR (62.9 MHz, CDCl3): δ = 16.1,
16.6, 21.2, 72.0, 122.4, 124.3, 126.6, 128.6, 129.4, 137.7, 138.6,
139.1, 147.9, 149.0, 158.5, 173.1. MS (DCI/H2O): m/z (%) = 409
(100) [C20H21N6S2]+. Anal.
Calcd for C20H20N6S2 (408.53):
C, 58.80; H, 4.93; N, 20.57; S, 15.69. Found: C, 58.54; H, 5.08;
N, 20.62; S, 15.53.
5-Methyl-2-(4-methylphenyl)-
N
′-(5-methyl-1,3,4-thiadiazol-2-yl)-
N
-(4-methylphenyl)-1,3,4-thiadiazole-3(2
H
)-carboximidamide (6b): Recrystallized from MeCN. 1H
NMR (250 MHz, CDCl3): δ = 2.12
(s, 3 H, CH3), 2.26 (s, 3 H, CH3), 2.32 (s,
3 H, CH3), 2.49 (s, 3 H, CH3), 7.12 (s, 1 H,
2-CH), 6.95-7.26 (m, 8 H, CHph), 10.03 (s, 1
H, NH). 13C NMR (62.9 MHz, CDCl3): δ = 16.8,
17.0, 21.3, 21.6, 72.3, 122.8, 126.9, 129.6, 129.7, 134.4, 136.8,
138.2, 139.0, 148.1, 148.7, 155.2, 173.5. MS (DCI/H2O): m/z (%) = 423(100) [C21H23N6S2]+.
Anal. Calcd for C21H22N6S2 (422.56):
C, 59.69; H, 5.25; N, 19.89; S, 15.17. Found: C, 59.58; H, 5.33;
N, 20.28; S, 15.05.
5-Methyl-2-(4-methylphenyl)-
N
′-(5-methyl-1,3,4-thiadiazol-2-yl)-
N
-(3-nitrophenyl)-1,3,4-thiadiazole-3(2
H
)-carboximidamide (6c): Purified by column chromatography. 1H
NMR (250 MHz, CDCl3): δ = 1.99
(s, 3 H, CH3), 2.23 (s, 3 H, CH3), 2.49 (s,
3 H, CH3), 6.96 (s, 1 H, 2-CH), 7.19-7.87 (m,
8 H, CHph), 10.59 (s, 1 H, NH). 13C NMR
(62.9 MHz, CDCl3): δ = 16.5,
16.9, 21.6, 72.2, 117.4, 118.9, 125.5, 127.7, 127.9, 129.5, 137.6,
138.4, 141.0, 148.4, 148.6, 149.5, 159.7, 173.7. MS (DCI/H2O): m/z (%) = 454
(81) [C20H20N7O2S2]+.
Anal. Calcd for C20H19N7O2S2 (453.53):
C, 52.97; H, 4.22; N, 21.62; O, 7.06; S, 14.14. Found: C, 52.80;
H, 4.38; N, 21.57; S, 13.83.
5-Methyl-2-(4-methylphenyl)-
N
′-(5-methyl-1,3,4-thiadiazol-2-yl)-
N
-(4-
t
-butylphenyl)-1,3,4-thiadiazole-3(2
H
)-carboximidamide (6d): Purified by column chromatography
and recrystallized from Et2O. 1H
NMR (250 MHz, CDCl3): δ = 1.32
(s, 9 H, CH3), 2.11 (s, 3 H, CH3), 2.36 (s,
3 H, CH3), 2.53 (s, 3 H, CH3), 7.01-7.16
(AA′/XX′, 4 H, CHph), 7.13
(s, 1 H, 2-CH), 7.27-7.29 (AA′/XX′, 4
H, CHph), 10.02 (br s, 1 H, NH). 13C
NMR (62.9 MHz, CDCl3): δ = 16.1,
16.6, 21.2, 31.3, 34.4, 72.0, 122.1, 125.5, 126.4, 129.4, 136.3,
137.8, 138.6, 147.4, 147.8, 149.2, 158.7, 173.0. MS (DCI/H2O): m/z (%) = 465(100) [C24H29N6S2]+.
Anal. Calcd for C24H28N6S2 (464.65):
C, 62.04; H, 6.07; N, 18.09; S, 13.80. Found: C, 61.98; H, 6.47; N,
18.40; S, 13.93.
5-Methyl-2-(4-methylphenyl)-
N
′-(5-methyl-1,3,4-thiadiazol-2-yl)-
N
-(4-methoxyphenyl)-1,3,4-thiadiazole-3(2
H
)-carboximidamide (6e): Recrystallized from EtOAc. 1H
NMR (250 MHz, CDCl3): δ = 2.10
(s, 3 H, CH3), 2.32 (s, 3 H, CH3), 2.54 (s,
3 H, CH3), 3.81 (s, 3 H, OCH3), 6.78-7.00 (AA′/XX′,
4 H, CHph), 7.11 (s, 1 H, 2-CH), 7.15-7.26 (AA′/XX′,
4 H, CH), 10.08 (br s, 1 H, NH). 13C
NMR (62.9 MHz, CDCl3): δ = 16.5,
17.0, 21.5, 55.8, 72.4, 114.2, 124.9, 126.9, 129.7, 132.5, 138.3,
139.0, 147.9, 150.0, 157.1, 159.1, 173.7. MS (DCI/H2O): m/z (%) = 439
(439) [C21H23N6OS2]+.
Anal. Calcd for C21H22N6OS2 (438.56):
C, 57.51; H, 5.06; N, 19.16; O, 3.65; S, 14.12. Found: C, 57.47; H,
5.31; N, 19.10; S, 14.24.
5-Methyl-2-(4-methylphenyl)-
N
′-(5-methyl-1,3,4-thiadiazol-2-yl)-
N
-(2-methoxyphenyl)-1,3,4-thiadiazole-3(2
H
)-carboximidamide (6f): Recrystallized from EtOAc. 1H
NMR (250 MHz, CDCl3): δ = 2.12
(s, 3 H, CH3), 2.38 (s, 3 H, CH3), 2.53 (s,
3 H, CH3), 3.88 (s, 3 H, OCH3), 6.76-7.29 (m,
8 H, CHph, 1 H, 2-CH), 9.71 (br s, 1 H, NH). 13C
NMR (62.9 MHz, CDCl3): δ = 16.1,
16.5, 21.5, 56.1, 72.2, 110.9, 120.6, 122.9, 125.0, 126.7, 128.5,
129.7, 138.3, 138.9, 148.3, 149.2, 151.2, 159.2, 172.8. MS (DCI/H2O): m/z (%) = 439
(100) [C21H23N6OS2]+.
Anal. Calcd for C21H22N6OS2 (438.56):
C, 57.51; H, 5.06; N, 19.16; S, 14.12. Found: C, 56.91; H, 5.32;
N, 18.67; S, 14.04.
2-Butyl-5-methyl-2-
N
′-(5-methyl-1,3,4-thiadiazol-2-yl)-
N
-phenyl-1,3,4-thiadiazole-3(2
H
)-carboximidamide (6g): Purified by column chromatography. 1H
NMR (250 MHz, CDCl3): δ = 0.91
(t, 3 H, CH3), 1.21-1.40 (m, 4 H, CH2),
1.89-2.21 (m, 2 H, CH2), 2.06 (s, 3 H, CH3),
2.57 (s, 3 H, CH3), 6.18-6.22 (t, 1 H, 2-CH),
7.02-7.29 (m, 5 H, CHph), 9.86 (s, 1 H, NH). 13C
NMR (62.9 MHz, CDCl3): δ = 14.3,
16.5, 17.2, 22.4, 27.1, 36.7, 71.7, 122.6, 124.7, 129.0, 139.5,
149.5, 150.1, 159.1, 173.4. MS (DCI/H2O): m/z (%) = 375
(100) [C17H23N6S2]+.
Anal. Calcd for C17H22N6S2 (374.52):
C, 54.52; H, 5.92; N, 22.44; S, 17.12. Found: C, 54.59; H, 6.31;
N 22.60; S, 16.75.
2-Butyl-5-methyl-2-
N
′-(5-methyl-1,3,4-thiadiazol-2-yl)-
N
-(2-hydroxyphenyl)-1,3,4-thiadiazole-3(2
H
)-carboximidamide (6h): Purified by column chromatography. 1H
NMR (250 MHz, CDCl3): δ = 0.91
(t, 3 H, CH3), 1.28-1.40 (m, 4 H, CH2),
2.07-2.21 (m, 2 H, CH2), 2.16 (s, 3 H, CH3),
2.56 (s, 3 H, CH3), 6.75-6.81 (t, 1 H, 2-CH),
6.93-7.07 (m, 4 H, CHph), 6.17 (s, 1 H, NH), 8.94 (s,
1 H, OH). 13C NMR (62.9 MHz, CDCl3): δ = 14.1,
16.5, 17.1, 22.7, 26.9, 36.4, 71.3, 117.6, 120.3, 125.3, 126.9,
127.5, 150.8, 151.2, 151.3, 159.6, 172.7. MS (DCI/H2O): m/z (%) = 391(100) [C17H23N6OS2]+.
Anal. Calcd for C17H22N6OS2 (390.52):
C, 52.29; H, 5.68; N, 21.52; O, 4.10; S, 16.42. Found: C, 51.76;
H, 5.88; N, 21.53; S, 16.29.
5-Methyl-2-naphthyl-
N
′-(5-methyl-1,3,4-thiadiazol-2-yl)-
N
-phenyl-1,3,4-thiadiazole-3(2
H
)-carboximidamide (6i): Purified by column chromatography. 1H
NMR (250 MHz, CDCl3): δ = 2.10
(s,
3 H, CH3), 2.44 (s, 3 H, CH3), 7.09-7.95
(m, 12 H, CHph;naphthyl), 7.95 (s, 1 H, 2-CH), 10.03
(s, 1 H, NH). 13C NMR (62.9 MHz, CDCl3): δ = 16.4,
17.1, 69.8, 123.0, 123.1, 124.2, 124.8, 125.9, 126.3, 126.9, 129.0,
129.5, 129.6, 129.8, 134.4, 136.1, 139.5, 149.3, 149.8, 159.4, 173.3.
MS (DCI/H2O): m/z (%) = 445
(100) [C23H21N6S2]+. Anal.
Calcd for C23H20N6S2 (444.57):
C, 62.14; H, 4.53; N, 18.90; S, 14.42. Found: C, 61.90; H, 4.60;
N, 19.25; S, 14.32.
5-Methyl-2-naphthyl-
N
′-(5-methyl-1,3,4-thiadiazol-2-yl)-
N
-(4-
t
-butylphenyl)-1,3,4-thiadiazole-3(2
H
)-carboximidamide (6j): Purified by column chromatography. 1H
NMR (250 MHz, CDCl3): δ = 1.33
(s, 9 H, CH3), 2.09 (s, 3 H, CH3), 2.42 (s,
3 H, CH3), 7.08-7.29 (AA′/XX′,
4 H, CHph), 7.48-7.93 (m, 7 H, CHnaphthyl),
7.91 (s, 1 H, 2-CH), 9.98 (s, 1 H, NH). 13C
NMR (62.9 MHz, CDCl3): δ = 16.2,
17.0, 31.8, 34.8, 69.7, 122.4, 122.7, 123.5, 125.5, 125.6, 125.9,
126.3, 126.8, 129.1, 129.2, 134.4, 136.1, 136.6, 147.9, 149.5, 149.8,
159.7, 173.2. MS (DCI/H2O): m/z (%) = 501
(100) [C27H29N6S2]+.
Anal. Calcd for C27H28N6S2 (500.67):
C, 64.77; H, 5.64; N, 16.79; S, 12.81. Found: C, 64.53; H, 6.14;
N, 16.51; S, 12.39.
5-Methyl-2-naphthyl-
N
′-(5-methyl-1,3,4-thiadiazol-2-yl)-
N
-(4-methoxyphenyl)-1,3,4-thiadiazole-3(2
H
)-carboximidamide (6k): Recrystallized from EtOH. 1H NMR
(250 MHz, CDCl3): δ = 2.10
(s, 3 H, CH3), 2.44 (s, 3 H, CH3), 3.83 (s,
3 H, OCH3), 6.81-7.08 (AA′/XX′,
4 H, CHph), 7.48-7.93 (m, 7 H, CHnaphthyl),
7.89 (s, 1 H, 2-CH). 13C NMR (62.9
MHz, CDCl3): δ = 16.3,
17.1, 55.9, 69.8, 114.2, 123.1, 124.2, 125.2, 126.0, 126.3, 126.8,
129.4, 129.5, 129.6, 132.4, 134.4, 136.3, 149.3, 150.0, 157.3, 159.2,
173.5. MS (DCI/H2O): m/z (%) = 475
(100) [C24H23N6OS2]+.
Anal. Calcd for C24H22N6OS2 (474.57):
C, 60.74; H, 4.67; N, 17.71; O, 3.37; S, 13.51. Found: C, 60.57; H,
4.87; N, 17.90; S, 13.20.
5-Methyl-2-naphthyl-
N
′-(5-methyl-1,3,4-thiadiazol-2-yl)-
N
-(2-hydroxyphenyl)-1,3,4-thiadiazole-3(2
H
)-carboximidamide (6l): Recrystallized from EtOAc. 1H NMR
(250 MHz, CDCl3): δ = 2.14
(s, 3 H, CH3), 2.28 (s, 3 H, CH3), 6.79-7.08
(m, 4 H, CHph), 7.49 (s, 1 H, NH), 7.38-7.83
(m, 7 H, CHnaphthyl), 7.95 (s, 1 H, 2-CH), 9.13 (s, 1
H, OH). 13C NMR (62.9 MHz, CDCl3): δ = 16.2,
16.9, 69.1, 118.4, 120.4, 122.7, 123.7, 125.7, 126.1, 126.3, 126.9, 127.0,
128.0, 129.4, 129.9, 134.3, 2 × 135.3,
150.4, 150.6, 151.7, 160.0, 171.5. MS (DCI/H2O): m/z (%) = 461(94) [C23H21N6OS2]+.
Anal. Calcd for C17H22N6OS2 (460.57):
C, 59.98; H, 4.38; N, 18.25; O, 3.47; S, 13.92. Found: C, 59.57; H,
4.70; N, 18.09; S, 13.71.
5-
t
-Butyl-2-(2-hydroxyphenyl-
N
′-(5-
t
-butyl-1,3,4-thiadiazol-2-yl)-
N
-(4-
t
-butylphenyl)-1,3,4-thiadiazole-3(2
H
)-carboximidamide (6m): Recrystallized from Et2O. 1H
NMR (250 MHz, CDCl3): δ = 0.99
(s, 9 H, CH3), 1.28 (s, 9 H, CH3), 1.42 (s,
9 H, CH3), 6.84-7.41 (m, 9 H, CHph,
2-CH), 11.0 (s, br, 1 H, OH), 11.16 (br s, 1 H, NH). 13C
NMR (62.9 MHz, CDCl3): δ = 28.8,
31.1, 31.7, 34.8, 36.6, 36.7, 66.4, 119.5, 121.3, 123.8, 125.7,
126.4, 129.4, 131.3, 137.0, 148.4, 150.8, 154.9, 163.8, 172.4, 174.3.
MS (DCI/H2O):
m/z (%) = 551(20) [C29H39N6OS2]+.
Anal. Calcd for C29H38N6OS2 (550.78):
C, 63.24; H, 6.95; N, 15.26; S, 11.64. Found: C, 63.03; H, 7.43;
N, 15.37; S, 11.43.
General Procedure
for the Formation of 2-(Het)arylamino-5-methyl-1,3,4-thiadiazoles
7: The suspension of 1 (5 mmol) and
amine 2 (10.1 mmol) in pyridine (60 mL)
was stirred at r.t. for 24-60 h.
[11a]
The reaction
mixture, changing to a nearly clear solution, was concentrated to
dryness in vacuo. The solid residue was washed off with water and
recrystallized as described in the literature.
[14]
[16]
The novel compound 7e was purified by column chromatography
and fractional crystallization from CHCl3/EtOAc
to prepare crystalline material suitable for X-ray investigation.
N
-(5-methyl-1,3,4-thiadiazol-2-yl)pyridin-2-amine (7e): Purified by column chromatography
and crystallized from EtOAc. 1H NMR (250 MHz,
DMSO-d
6): δ = 2.56
(s, 3 H, CH3), 6.94 (t, 1 H, pyridine-5 H), 7.05 (d,
1 H, pyridine-3 H), 7.68 (dd, 1 H, pyridine-4 H), 8.24 (d, 1 H,
pyridine-6 H), 11.44 (s, 1 H, NH). 13C
NMR (62.9 MHz, DMSO-d
6): δ = 14.6
(CH3), 111.0 (pyridine-5C), 116.5 (pyridine-4C), 138.3
(pyridine-3C), 146.5 (pyridine-6C), 150.9 (pyridine-2C), 156.9 (thiadiazole-5C),
159.9 (thiadiazole-2C). MS (DEI): m/z (%) = 192(100) [ C8H8N4S]+.
Anal. Calcd for C8H8N4S (192.2):
C, 49.98; H, 4.19; N, 29.14; S, 16.68. Found: C, 50.22; H, 4.18;
N, 28.83; S, 16.47.
CCDC 210984 and 210985 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB2 1EZ, UK; fax: +44(1223)336033; or deposit@ccdc.cam.ac.uk).